Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | KIF11 | P52732 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHKA | P35790 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18612742 | 0.92 | ESR1 (0.40) | ESR1ESR2KIF11CYP3A4CYP2D6 | |
| SCHEMBL13370709 | 0.91 | ESR1 (0.42) | ESR1ESR2KIF11CYP3A4CYP2D6 | |
| SCHEMBL21185893 | 0.90 | ESR1 (0.39) | ESR1ESR2KIF11CYP3A4CYP2D6 | |
| SCHEMBL21695082 | 0.89 | CNR2 (0.39) | ESR1ESR2KIF11CYP3A4CYP2D6 | |
| SCHEMBL19440675 | 0.87 | CYP3A4 (0.40) | ESR1ESR2KIF11CYP3A4CYP2D6 | |
| SCHEMBL19059382 | 0.85 | CYP3A4 (0.39) | ESR1ESR2KIF11CYP3A4CYP2D6 | |
| SCHEMBL24871939 | 0.84 | CNR2 (0.40) | KIF11CYP3A4CYP2D6CYP19A1LMNA | |
| SCHEMBL19274594 | 0.84 | CYP3A4 (0.38) | ESR1ESR2KIF11CYP3A4CYP2D6 | |
| SCHEMBL24475344 | 0.84 | CNR2 (0.40) | KIF11CYP3A4CYP2D6CYP19A1LMNA | |
| SCHEMBL19223950 | 0.84 | CNR2 (0.40) | KIF11CYP3A4CYP2D6CYP19A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730723-B2 | Compounds and methods for treating viral infections | LEXICON PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11724998-B2 | PXR agonists and uses thereof for gut barrier dysfunction treatment and prevention | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| EP-3561876-B1 | DISPLAY | NOVALED GMBH (DE) | 2022-02-16 | — | — | EP | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024859-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | ESR1 3535/4885ESR2 2587/4885KIF11 4586/4885 |
| US-11730723-B2 | Compounds and methods for treating viral infections | EIF2AK2, SARS1, MAVS | ESR1 4302/4885ESR2 3222/4885KIF11 1992/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | ESR1 1662/4885ESR2 2553/4885KIF11 4086/4885 |
| US-11724998-B2 | PXR agonists and uses thereof for gut barrier dysfunction treatment and prevention | NR1H2, NR1H4, NR1H3 | ESR1 731/4885ESR2 207/4885KIF11 4628/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | ESR1 1662/4885ESR2 2553/4885KIF11 4086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.